What happens when a generic or biosimilar enters a market where patents are in force? What preliminary measures exist?
On February 23, our professionals from the UK, Canada, China and France hosted a live webinar exploring global perspectives on the use of preliminary injunctions (PIs) in the life sciences sector. Over the course of the event, our team will answer a range of important questions, including:
- How common are PIs across various jurisdictions?
- When might a PI be sought – upon launch or marketing approval?
- What is the procedure for seeking a PI?
- What are the unique considerations for life sciences companies?
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.